Target audience
Hospitals and oncology departments, SMEs, startups and large companies, Community health organizations and SMOs, Academics and research organizations, Cancer patients, survivors and caregivers, Patients and survivors representative organizations, Oncology-centred living labs and Social sciences and humanities experts
The project
Collaborative consortium of at least three beneficiaries, working together around a research and innovation or coordination and support action, responding to specific challenges mentioned in the topic and implementing the expected outcomes, within a project lasting an average of 3 years.
EU funding
The EU funding covers between 70%-100% of the project costs, plus overhead of 25% of the project budget for indirect expenses. In each topic, the European commission mentions the indicative budget per project.
More information about this programme
Open calls
Call identifier
Deadline
Type of action
Budget overview
Indicative number of grants
Development of a research capacity building programme on cancer with and for Ukraine
HORIZON-MISS-2026-02-CANCER-06
Last date for submission15-09-2026
CSA
Microbiome for early cancer prediction before the onset of disease
HORIZON-MISS-2026-02-CANCER-02
Last date for submission15-09-2026
RIA
Improve the Quality of Life of older cancer patients
HORIZON-MISS-2026-02-CANCER-07
Last date for submission15-09-2026
RIA
Boosting mental health of young cancer survivors through the European Cancer Patient Digital Centre (ECPDC)
HORIZON-MISS-2026-02-CANCER-05
Last date for submission15-09-2026
IA
Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers
HORIZON-MISS-2026-02-CANCER-03
Last date for submission15-09-2026
RIA
Virtual Human Twin (VHT) Models for Cancer Research
HORIZON-MISS-2026-02-CANCER-01
Last date for submission15-09-2026
RIA
Earlier and more precise palliative care
HORIZON-MISS-2026-02-CANCER-04
Last date for submission15-09-2026
RIA
Living labs to monitor and mitigate carcinogenic substances in and originating from soils: Evaluating their effects on human cancer risks
HORIZON-MISS-2027-06-SOIL-CANCER
Last date for submission21-09-2027
RIA
Leveraging functional genomics to reveal novel targets for cancer treatment
HORIZON-MISS-2027-02-CANCER-01
Last date for submission21-09-2027
RIA
Clinical research by Comprehensive Cancer Infrastructures for the benefit of patients with common cancers
HORIZON-MISS-2027-02-CANCER-02
Last date for submission21-09-2027
IA
Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
HORIZON-MISS-2027-02-CANCER-03
Last date for submission21-09-2027
RIA
Improving equitable health outcomes and added value for and with cancer patients through health-economics research, health systems research and outcomes research
HORIZON-MISS-2027-02-CANCER-04
Last date for submission21-09-2027
RIA
Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines
HORIZON-MISS-2027-02-CANCER-05
Last date for submission21-09-2027
Other Type
Support a Young Cancer Survivor Quality of Life (QoL) research programme by cancer charities and funding agencies
HORIZON-MISS-2027-02-CANCER-06
Last date for submission21-09-2027
CSA
No matching results were found for your search